{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T01:52:08Z","timestamp":1781315528784,"version":"3.54.1"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T00:00:00Z","timestamp":1707436800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,8,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Aims<\/jats:title>\n                  <jats:p>Patients with cancer are at increased cardiovascular (CV) risk. We aimed to compare the recommended and observed statin use among individuals with and without cancer.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods and results<\/jats:title>\n                  <jats:p>Using three 2-year cycles from the National Health and Nutrition Examination Survey (2013\u201318), we analysed data from 17 050 US adults. We compared the prevalence of Class 1 statin recommendations and use between individuals with and without cancer, overall, and among different demographic groups. Individuals with a history of cancer were older and had a higher burden of comorbidities. Stratified by age groups, they were more likely to have a secondary prevention indication compared with individuals without cancer but not a primary prevention indication for statin. Among individuals with an indication for statin therapy, the prevalence of statin use was higher in the cancer group compared with those without cancer (60.8% vs. 47.8%, P &amp;lt; 0.001), regardless of sex, type of indication (primary vs. secondary prevention), and education level. However, the higher prevalence of statin use in the cancer group was noted among younger individuals, ethnic minorities, and those with lower family income.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Our finding highlights the importance of optimization of CV health in patients with cancer, as individuals with cancer were more likely to have a Class 1 indication for statin treatment when compared with individuals without cancer. Important differences in statin use among cohorts based on sex, age, ethnicity, and socioeconomic status were identified, which may provide a framework through which CV risk factor control can be targeted in this population.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Key findings<\/jats:title>\n                  <jats:p>Higher statin use in cancer patients: Among those with Class 1 recommendation to take statins, 60.8% of cancer patients were using them, compared with 47.8% of non-cancer individuals, indicating a greater adherence to heart health recommendations in the cancer group. Demographic variations in statin use: The study found notable differences in statin use among younger individuals, ethnic minorities, and those with lower income within the cancer patient group, suggesting disparities in how these subgroups manage their cardiovascular health.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/eurjpc\/zwae057","type":"journal-article","created":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T08:40:02Z","timestamp":1707468002000},"page":"1251-1257","source":"Crossref","is-referenced-by-count":10,"title":["Recommended and observed statin use among US adults with and without cancer"],"prefix":"10.1093","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7418-498X","authenticated-orcid":false,"given":"Ofer","family":"Kobo","sequence":"first","affiliation":[{"name":"Keele Cardiovascular Research Group, Centre for Prognosis Research, Keele University , Stoke-on-Trent, Straffordshire ST5 5BG , UK"},{"name":"Department of Cardiology, Hillel Yaffe Medical Center , Hadera , Israel"},{"name":"Ruth and Bruce Rappaport School of Medicine, Technion-Israel Institute of Technology, Haifa, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5547-5084","authenticated-orcid":false,"given":"Erin D","family":"Michos","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Johns Hopkins University School of Medicine , Baltimore, MD , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariel","family":"Roguin","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Hillel Yaffe Medical Center , Hadera , Israel"},{"name":"Ruth and Bruce Rappaport School of Medicine, Technion-Israel Institute of Technology, Haifa, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo","family":"Bagur","sequence":"additional","affiliation":[{"name":"London Health Sciences Centre, Western University , London, Ontario , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha","family":"Gulati","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Barbra Streisand Women\u2019s Heart Center, Smidt Heart Institute, Cedars Sinai Medical Center , Los Angeles, CA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9241-8890","authenticated-orcid":false,"given":"Mamas A","family":"Mamas","sequence":"additional","affiliation":[{"name":"Keele Cardiovascular Research Group, Centre for Prognosis Research, Keele University , Stoke-on-Trent, Straffordshire ST5 5BG , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,2,9]]},"reference":[{"key":"2024080903372832300_zwae057-B1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21654","article-title":"Cancer statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"2024080903372832300_zwae057-B2","doi-asserted-by":"crossref","first-page":"e146","DOI":"10.1161\/CIR.0000000000000485","article-title":"Heart disease and stroke statistics-2017 update: a report from the American Heart Association","volume":"135","author":"Benjamin","year":"2017","journal-title":"Circulation"},{"key":"2024080903372832300_zwae057-B3","doi-asserted-by":"crossref","first-page":"363","DOI":"10.3322\/caac.21565","article-title":"Cancer treatment and survivorship statistics, 2019","volume":"69","author":"Miller","year":"2019","journal-title":"CA Cancer J Clin"},{"key":"2024080903372832300_zwae057-B4","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1093\/ehjqcco\/qcac016","article-title":"Temporal trends in disease-specific causes of cardiovascular mortality amongst patients with cancer in the USA between 1999 to 2019","volume":"9","author":"Raisi-Estabragh","year":"2022","journal-title":"Eur Hear J Qual care Clin outcomes"},{"key":"2024080903372832300_zwae057-B5","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.jaccao.2022.01.102","article-title":"Does cardiovascular mortality overtake cancer mortality during cancer survivorship?. An English retrospective cohort study","volume":"4","author":"Strongman","year":"2022","journal-title":"JACC CardioOncol"},{"key":"2024080903372832300_zwae057-B6","first-page":"e1082","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"139","author":"Grundy","year":"2019","journal-title":"Circulation"},{"key":"2024080903372832300_zwae057-B7","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"key":"2024080903372832300_zwae057-B8","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.jacl.2022.12.005","article-title":"Recommended and observed statin use among U.S. adults\u2014National Health and Nutrition Examination Survey, 2011\u20132018","volume":"17","author":"Thompson-Paul","year":"2023","journal-title":"J Clin Lipidol"},{"key":"2024080903372832300_zwae057-B9","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1093\/eurjpc\/zwac103","article-title":"Burden and predictors of statin use in primary and secondary prevention of atherosclerotic vascular disease in the US: from the National Health and Nutrition Examination Survey 2017\u20132020","volume":"29","author":"Chobufo","year":"2022","journal-title":"Eur J Prev Cardiol"},{"key":"2024080903372832300_zwae057-B10","doi-asserted-by":"crossref","first-page":"1606088","DOI":"10.3389\/ijph.2023.1606088","article-title":"The role of cancer in the risk of cardiovascular and all-cause mortality: a nationwide prospective cohort study","volume":"68","author":"Shen","year":"2023","journal-title":"Int J Public Health"},{"key":"2024080903372832300_zwae057-B11","doi-asserted-by":"crossref","first-page":"e030942","DOI":"10.1161\/JAHA.123.030942","article-title":"Cardiovascular health metrics differ between individuals with and without cancer","volume":"12","author":"Kobo","year":"2023","journal-title":"J Am Heart Assoc"},{"key":"2024080903372832300_zwae057-B12","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s12032-013-0561-4","article-title":"Appropriateness of cardiovascular care in elderly adult cancer survivors","volume":"30","author":"Cheung","year":"2013","journal-title":"Med Oncol"},{"key":"2024080903372832300_zwae057-B13","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.jaccao.2020.05.010","article-title":"Suboptimal use of cardioprotective medications in patients with a history of cancer","volume":"2","author":"Untaru","year":"2020","journal-title":"JACC CardioOncology"},{"key":"2024080903372832300_zwae057-B14","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1177\/2048872617729636","article-title":"Treatment of patients with myocardial infarction depends on history of cancer","volume":"7","author":"Rohrmann","year":"2018","journal-title":"Eur Hear J Acute Cardiovasc care"},{"key":"2024080903372832300_zwae057-B15","first-page":"1","article-title":"National health and nutrition examination survey: analytic guidelines, 1999\u20132010","volume":"161","author":"Johnson","year":"2013","journal-title":"Vital Health Stat 2"},{"key":"2024080903372832300_zwae057-B16","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1161\/01.cir.0000437738.63853.7a","article-title":"2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"129","author":"Stone","year":"2014","journal-title":"Circulation"},{"key":"2024080903372832300_zwae057-B17","doi-asserted-by":"crossref","first-page":"911","DOI":"10.14740\/jocmr3617w","article-title":"Comparison of comorbid conditions between cancer survivors and age-matched patients without cancer","volume":"10","author":"Roy","year":"2018","journal-title":"J Clin Med Res"},{"key":"2024080903372832300_zwae057-B18","first-page":"37","article-title":"Simplified rules-based tool to facilitate the application of up-to-date management recommendations in cardio-oncology","volume":"9","author":"Brown","year":"2023","journal-title":"Cardiooncology"},{"key":"2024080903372832300_zwae057-B19","doi-asserted-by":"crossref","first-page":"e2343861","DOI":"10.1001\/jamanetworkopen.2023.43861","article-title":"Statin use, cholesterol level, and mortality among females with breast cancer","volume":"6","author":"Murto","year":"2023","journal-title":"JAMA Netw open"},{"key":"2024080903372832300_zwae057-B20","doi-asserted-by":"crossref","first-page":"evidoa2200097","DOI":"10.1056\/EVIDoa2200097","article-title":"Statins and left ventricular ejection fraction following doxorubicin treatment","volume":"1","author":"Hundley","year":"2022","journal-title":"NEJM Evid"},{"key":"2024080903372832300_zwae057-B21","doi-asserted-by":"crossref","first-page":"115907","DOI":"10.1016\/j.bcp.2023.115907","article-title":"Targeting cholesterol metabolism in cancer: from molecular mechanisms to therapeutic implications","volume":"218","author":"Lu","year":"2023","journal-title":"Biochem Pharmacol"},{"key":"2024080903372832300_zwae057-B22","doi-asserted-by":"crossref","first-page":"18866","DOI":"10.1038\/s41598-023-45958-8","article-title":"Statin use and outcomes of oncological treatment for castration-resistant prostate cancer","volume":"13","author":"Peltomaa","year":"2023","journal-title":"Sci Rep"},{"key":"2024080903372832300_zwae057-B23","doi-asserted-by":"crossref","first-page":"5100","DOI":"10.3390\/cancers15205100","article-title":"Don\u2019t judge a book by its cover: the role of statins in liver cancer","volume":"15","author":"Pieku\u015b-S\u0142omka","year":"2023","journal-title":"Cancers (Basel)"},{"key":"2024080903372832300_zwae057-B24","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur Heart J"},{"key":"2024080903372832300_zwae057-B25","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1093\/ehjqcco\/qcad012","article-title":"Outcomes of ST elevation myocardial infarction in patients with cancer: a nationwide study","volume":"9","author":"Dafaalla","year":"2023","journal-title":"Eur Hear J Qual care Clin outcomes"},{"key":"2024080903372832300_zwae057-B26","doi-asserted-by":"crossref","first-page":"e71","DOI":"10.1016\/j.clbc.2023.10.007","article-title":"Atherosclerotic cardiovascular disease risk and longitudinal risk factor management among patients with breast cancer","volume":"24","author":"Melson","year":"2024","journal-title":"Clin Breast Cancer"},{"key":"2024080903372832300_zwae057-B27","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1001\/jamacardio.2023.0228","article-title":"Prevalence of statin use for primary prevention of atherosclerotic cardiovascular disease by race, ethnicity, and 10-year disease risk in the US: National Health and Nutrition Examination Surveys, 2013 to March 2020","volume":"8","author":"Jacobs","year":"2023","journal-title":"JAMA Cardiol"},{"key":"2024080903372832300_zwae057-B28","doi-asserted-by":"crossref","first-page":"807","DOI":"10.3122\/jabfm.2019.06.180313","article-title":"Statin use in the U.S. for secondary prevention of cardiovascular disease remains suboptimal","volume":"32","author":"Ngo-Metzger","year":"2019","journal-title":"J Am Board Fam Med"},{"key":"2024080903372832300_zwae057-B29","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.amjcard.2021.08.070","article-title":"Gaps and disparities in primary prevention statin prescription during outpatient care","volume":"161","author":"Metser","year":"2021","journal-title":"Am J Cardiol"},{"key":"2024080903372832300_zwae057-B30","doi-asserted-by":"crossref","first-page":"e6","DOI":"10.2196\/resprot.3407","article-title":"Development and evaluation of an educational E-tool to help patients with non-Hodgkin\u2019s lymphoma manage their personal care pathway","volume":"4","author":"Stienen","year":"2015","journal-title":"JMIR Res Protoc"},{"key":"2024080903372832300_zwae057-B31","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s00520-020-05422-z","article-title":"A portable survivorship care plan: a tool that helps educate and improve knowledge in childhood cancer survivors","volume":"29","author":"Murphy","year":"2021","journal-title":"Support care cancer"}],"container-title":["European Journal of Preventive Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurjpc\/advance-article-pdf\/doi\/10.1093\/eurjpc\/zwae057\/56756285\/zwae057.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjpc\/article-pdf\/31\/10\/1251\/58778553\/zwae057.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjpc\/article-pdf\/31\/10\/1251\/58778553\/zwae057.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,9]],"date-time":"2024-08-09T03:38:23Z","timestamp":1723174703000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjpc\/article\/31\/10\/1251\/7604140"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,9]]},"references-count":31,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2024,2,9]]},"published-print":{"date-parts":[[2024,8,9]]}},"URL":"https:\/\/doi.org\/10.1093\/eurjpc\/zwae057","relation":{},"ISSN":["2047-4873","2047-4881"],"issn-type":[{"value":"2047-4873","type":"print"},{"value":"2047-4881","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,8]]},"published":{"date-parts":[[2024,2,9]]}}}